Valneva begins U.K. approval process for COVID-19 vaccine

By The Science Advisory Board staff writers

August 23, 2021 -- French firm Valneva has begun the regulatory submission process to the U.K.'s Medicines and Healthcare products Regulatory Agency for its COVID-19 vaccine candidate, VLA2001.

The candidate is a whole-virus, inactivated, adjuvanted vaccine -- the only one of its kind in clinical trials in Europe, according to the company. The company is conducting a phase III trial for the vaccine and hopes to receive approval for it before the end of the year.

In September 2020, Valneva entered into an agreement with the U.K. government for the option to purchase up to 190 million doses of the vaccine through 2025, it said.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.